StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd

Bullboard Posts

Comment by jjwilsonon May 14, 2020 9:59am

120 Views

Post# 31027020

RE:RE:RE:Is our product inferior or unknown ?

"I'm saying so the the rapid response test has a palce but any positive would likely then lead to a full lab test. Either way lots of testing going around for the next few years!"

SAGDollar;

Yes, this is my feeling too. The rapid response tests will be sold and used by the billions but a positive result there will necessitate a proper lab test to confirm. This is where SZLS will make most of it's revenue (until Aristotle).

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale